New Delhi: New York headquartered, Ichnos Glenmark Innovation (IGI), a global fully-integrated clinical-stage biotech company developing multispecifics™ in oncology presented first-time data from its Phase 1 study of ISB 2001 in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA.
ISB 2001 is IGI’s first-in-class trispecific antibody targeting BCMA and CD38 on myeloma cells and CD3 on T cells, currently investigated in relapsed/refractory multiple myeloma (r/r MM).
“Although recent advancements have brought new therapeutic options to multiple myeloma patients, resistance mechanisms continue to limit their efficacy, necessitating multiple lines of treatment for many patients,” said Lida Pacaud, M.D., Chief Medical Officer at IGI. “We are encouraged by the early data from our Phase 1 study of ISB 2001, which shows a remarkable response rate and demonstrates potential to address these challenges in heavily pretreated patients.”
The oral presentation will detail results from the dose-escalation portion of the study. The abstract features data as of July 2024, including:
-
An overall response rate (ORR) of 75% (9/12) in efficacy-evaluable patients, including one (1) MRD negative stringent complete response (sCR)
-
A favorable safety and tolerability profile that showed no dose-limiting toxicities (DLTs), only one adverse event of special interest (AE) above Grade 2, and no treatment discontinuation.
 of 75% in Relapsed/Refractory Multiple Myeloma){kind=link}